JD HEALTH
06618
BIDU-SW
09888
JD-SW
09618
ALI HEALTH
00241
BEKE-W
02423
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | (Q6)Sep 30, 2020 | (FY)Mar 31, 2020 | (Q6)Sep 30, 2019 | (FY)Mar 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 1.50%2.67B | 34.43%4.83B | --2.63B | 19.35%3.59B | 20.73%1.74B | 8.20%3.01B | -5.40%1.44B | 111.52%2.78B | 82.38%1.52B | 6.14%1.31B |
Operating income | 1.50%2.67B | 34.43%4.83B | 2.63B | 19.35%3.59B | 20.73%1.74B | 8.20%3.01B | -5.40%1.44B | 111.52%2.78B | 82.38%1.52B | 6.14%1.31B |
Cost of sales | 2.06%-2.18B | -38.12%-4.15B | ---2.22B | -23.65%-3B | -25.86%-1.43B | -6.46%-2.43B | 8.42%-1.14B | -120.33%-2.28B | -90.82%-1.24B | -7.22%-1.04B |
Operating expenses | 2.06%-2.18B | -38.12%-4.15B | -2.22B | -23.65%-3B | -25.86%-1.43B | -6.46%-2.43B | 8.42%-1.14B | -120.33%-2.28B | -90.82%-1.24B | -7.22%-1.04B |
Gross profit | 21.04%490.2M | 15.61%679.91M | 404.99M | 1.36%588.1M | 1.51%308.36M | 16.13%580.22M | 7.95%303.77M | 78.85%499.61M | 52.57%281.4M | 2.33%279.35M |
Selling expenses | -17.15%-35.57M | 27.15%-48.11M | ---30.36M | -27.80%-66.04M | -32.53%-32.18M | -2.90%-51.68M | 9.80%-24.28M | -116.23%-50.22M | -126.57%-26.92M | -15.23%-23.23M |
Administrative expenses | -27.42%-87.33M | 8.37%-123.21M | ---68.54M | -9.67%-134.46M | -12.71%-66.32M | 0.83%-122.61M | 5.61%-58.84M | -113.61%-123.63M | -102.06%-62.34M | -68.30%-57.88M |
Research and development expenses | -46.42%-87.56M | 21.18%-95.66M | ---59.8M | -37.34%-121.35M | -61.02%-57.47M | -29.20%-88.36M | 6.45%-35.69M | -49.73%-68.39M | -51.59%-38.15M | -11.64%-45.67M |
Revaluation surplus | ---- | ---- | ---- | ---- | ---- | ---5.76M | ---5.19M | ---- | ---- | ---- |
Impairment and provision | 1,020.41%1.1M | ---1.33M | --98K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Other impairment is provision | 1,020.41%1.1M | ---1.33M | --98K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Special items of operating profit | 267.18%17.11M | 317.64%19.44M | ---10.24M | 493.49%4.66M | 159.16%2.55M | -168.50%-1.18M | -82.88%982K | 134.95%1.73M | 167.26%5.74M | -141.94%-4.94M |
Operating profit | 26.17%297.94M | 59.12%431.04M | 236.14M | -12.79%270.9M | -14.28%154.94M | 19.89%310.64M | 13.16%180.75M | 75.51%259.1M | 47.88%159.73M | -22.02%147.63M |
Financing cost | 13.35%-42.5M | -132.84%-88.58M | ---49.05M | 10.54%-38.04M | 16.24%-20.02M | 39.46%-42.53M | 31.58%-23.9M | -4,159.85%-70.25M | -3,072.39%-34.93M | 29.01%-1.65M |
Earning before tax | 36.53%255.44M | 47.07%342.46M | 187.09M | -13.15%232.86M | -13.98%134.93M | 41.97%268.11M | 25.68%156.86M | 29.37%188.85M | 16.74%124.8M | -14.64%145.98M |
Tax | -46.23%-52.28M | -0.42%-64.86M | ---35.75M | -55.69%-64.58M | -66.04%-43.48M | -20.69%-41.48M | -5.65%-26.19M | -49.13%-34.37M | -33.91%-24.79M | 40.75%-23.05M |
After-tax profit from continuing operations | 34.24%203.16M | 64.97%277.61M | 151.34M | -25.75%168.27M | -30.02%91.45M | 46.70%226.63M | 30.65%130.67M | 25.66%154.48M | 13.14%100.02M | -6.95%122.93M |
Earning after tax | 34.24%203.16M | 64.97%277.61M | 151.34M | -25.75%168.27M | -30.02%91.45M | 46.70%226.63M | 30.65%130.67M | 25.66%154.48M | 13.14%100.02M | -6.95%122.93M |
Minority profit | 144.35%562K | 826.00%463K | --230K | -81.48%50K | -5.15%258K | -33.17%270K | -1.81%272K | --404K | --277K | ---- |
Profit attributable to shareholders | 34.07%202.6M | 64.75%277.14M | 151.11M | -25.68%168.22M | -30.07%91.19M | 46.91%226.36M | 30.74%130.4M | 25.34%154.08M | 12.83%99.74M | -6.95%122.93M |
Basic earnings per share | 33.98%0.1041 | 56.48%0.1424 | 0.0777 | -26.02%0.091 | -30.18%0.0495 | 46.95%0.123 | 30.81%0.0709 | 25.30%0.0837 | 12.92%0.0542 | -23.04%0.0668 |
Diluted earnings per share | 33.98%0.1041 | 58.05%0.1424 | 0.0777 | -26.75%0.0901 | -30.89%0.049 | 48.19%0.123 | 32.52%0.0709 | 24.25%0.083 | 11.46%0.0535 | 0.0668 |
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Hong Kong Lixin Dehao Certified Public Accountants Limited | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.